Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03531892
Recruitment Status : Active, not recruiting
First Posted : May 22, 2018
Last Update Posted : May 19, 2021
Sponsor:
Collaborator:
Kissei Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Eisai Inc. ( EA Pharma Co., Ltd. )

Brief Summary:
The study will investigate the efficacy and safety of an oral dose of AJM300 960 milligram (mg)/dose administered three times daily for 8 weeks in participants with active ulcerative colitis.

Condition or disease Intervention/treatment Phase
Colitis, Ulcerative Drug: AJM300 Drug: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 198 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase III Study of AJM300 in Patients With Active Ulcerative Colitis
Actual Study Start Date : June 6, 2018
Actual Primary Completion Date : December 16, 2020
Estimated Study Completion Date : March 31, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: AJM300 960mg/dose
Participants will orally receive AJM300 960 mg tablets, three times daily after meals for 8 weeks.
Drug: AJM300
AJM300 film-coated tablets.
Other Name: Carotegrast methyl

Placebo Comparator: Placebo
Participants will orally receive AJM300 placebo-matching tablets, three times daily after meals for 8 weeks.
Drug: Placebo
Placebo matched to AJM300 tablets.




Primary Outcome Measures :
  1. Clinical Response Rate Based on Mayo Score [ Time Frame: At Week 8 ]
    Clinical response rate is defined by the percentage of participants who satisfy the combined definition of the change of the total value of Mayo score and the change or the actual value of individual subscales. Mayo score is used in clinical trials to assess ulcerative colitis (UC) disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0= normal condition and 3= severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.


Secondary Outcome Measures :
  1. Clinical Remission Rate Based on Mayo Score [ Time Frame: At Week 8 ]
    Clinical remission rate is defined by the percentage of participants with Mayo score <=2 and no subscore greater than (>) 1.

  2. Mucosal Healing Rate [ Time Frame: At Week 8 ]
    Mucosal healing rate is defined by the percentage of participants with Mayo endoscopic subscore <=1.

  3. Complete Mucosal Healing Rate [ Time Frame: At Week 8 ]
    Complete mucosal healing rate is defined by the percentage of participants with Mayo endoscopic subscore =0.

  4. Clinical Response Rate Based on Partial Mayo Score [ Time Frame: At Week 8 ]
    Clinical response rate is defined by the percentage of participants who satisfy the combined definition of the change of the total value of partial Mayo score and the change or the actual value of individual subscales. Partial Mayo score is used in clinical trials to assess UC disease activity. It consists of 3 subscales: stool frequency, rectal bleeding and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0= normal condition and 3= severe disease condition. The total partial Mayo score ranges from 0 to 9, with higher scores indicating more severe disease.

  5. Clinical Remission Rate Based on Partial Mayo Score [ Time Frame: At Week 8 ]
    Clinical remission rate is defined by the percentage of participants with partial Mayo score <=2 and no subscore >1.

  6. Modified Clinical Remission Rate 1 [ Time Frame: At Week 8 ]
    Modified Clinical remission rate 1 is defined by percentage of participants who satisfies the three conditions such as: rectal bleeding subscore =0, Stool frequency subscore =0 and Endoscopic subscore <=1.

  7. Modified Clinical Remission Rate 2 [ Time Frame: At Week 8 ]
    Modified Clinical remission rate 2 is defined by the percentage of participants who satisfies the three conditions such as: rectal bleeding subscore =0, a decrease in the stool frequency subscore of at least 1 point or an absolute stool frequency subscore of 0 or 1 and Endoscopic subscore <=1.

  8. Percentage of Rectal Bleeding Subscore of 0 [ Time Frame: At Week 8 ]
    Percentage of rectal bleeding subscore of 0 means the percentage of participants with rectal bleeding score =0.

  9. Change From Baseline in Mayo score [ Time Frame: Baseline, Week 8 ]
    Mayo score is used in clinical trials to assess UC disease activity. It consists of 4 subscales: stool frequency, rectal bleeding, findings on endoscopy and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0= normal condition and 3= severe disease condition. The total Mayo score ranges from 0 to 12, with higher scores indicating more severe disease.

  10. Change From Baseline in Partial Mayo Score [ Time Frame: Baseline, Week 8 ]
    Partial Mayo score is used in clinical trials to assess UC disease activity. It consists of 3 subscales: stool frequency, rectal bleeding and physician's global assessment. Each subscale is scored on a scale of 0 to 3, where 0= normal condition and 3= severe disease condition. The total Mayo score ranges from 0 to 9, with higher scores indicating more severe disease.

  11. Change From Baseline in Fecal Calprotectin [ Time Frame: Baseline, Week 8 ]
  12. Change From Baseline in Peripheral Blood White Blood Cell (WBC) Differentiation (Neutrophil, Eosinophil, Basophil, Lymphocyte, and Monocyte Counts) [ Time Frame: Baseline, Week 8 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 74 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Major Inclusion Criteria:

  1. Participants diagnosed with ulcerative colitis.
  2. Participants with moderate ulcerative colitis who satisfy all of the following criteria at Day of enrollment.

    1. Mayo Clinic scores of 6-10 .
    2. Endoscopic subscore greater than or equal to (>=) 2.
    3. Rectal bleeding subscore >=1.
  3. Participants with inadequate response or intolerant to oral 5-ASA
  4. Participants who are capable of providing written informed consent

Major Exclusion Criteria:

  1. Participants with extensive detachment of mucosa or deep ulcer.
  2. Participants with oral corticosteroid dependency.
  3. Participants with a complication of marked reduction of immune function.
  4. Participants who were clinically suspected to have a complication of infectious enteritis.
  5. Participants with a history or complication of serious infection within 1 year prior to the day of enrollment.
  6. Participants with central nervous system (CNS) neurological symptoms.
  7. Participants with the following criteria:

    • Serious heart disease
    • Renal impairment
    • Hepatic impairment
  8. Participants with a history of serious drug induced allergy with unknown cause.
  9. Participants with malignant tumor or those whose treatments were completed in less than 5 years.
  10. Participants with apparent psychological signs.
  11. Pregnant women, nursing women, women with suspected pregnancy, women who wish to become pregnant during the period from informed consent through to the end of observation/examination at Week 8, and women who do not consent to the use of appropriate birth control methods.
  12. Participants who are definitely eligible for surgical intervention such as large bowel perforation, major bleeding, and toxic megacolon syndrome, etc.
  13. Participants who are participants of another clinical study including follow-up observation at the time of informed consent.
  14. Participants who received another investigational drug within 12 weeks prior to the examinations/observation defined by the protocol.
  15. Participants who received investigational drugs in the study of AJM300.
  16. Participants determined to be ineligible for participation in this study by the investigator or sub-investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03531892


Locations
Show Show 82 study locations
Sponsors and Collaborators
EA Pharma Co., Ltd.
Kissei Pharmaceutical Co., Ltd.
Layout table for additonal information
Responsible Party: EA Pharma Co., Ltd.
ClinicalTrials.gov Identifier: NCT03531892    
Other Study ID Numbers: AJM300/CT3
JapicCTI-183924 ( Registry Identifier: JapicCTI )
First Posted: May 22, 2018    Key Record Dates
Last Update Posted: May 19, 2021
Last Verified: May 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Eisai Inc. ( EA Pharma Co., Ltd. ):
Ulcerative Colitis
Inflammatory Bowel Disease, Ulcerative Colitis Type
Colitis
AJM300
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Pathologic Processes
Inflammatory Bowel Diseases